Kymera Therapeutics, Inc. Common Stock
KYMR
$99.45
+9.97%
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, targeted protein degradation therapies for diseases with high unmet medical need, operating within the biotechnology industry. The company is a pioneer in its field, leveraging its proprietary Pegasus platform to drug historically challenging targets, positioning it as a potential disruptor in the treatment of inflammatory, autoimmune, and oncological diseases. The current investor narrative is driven by clinical progress for its lead programs, STAT6 and IRAK4 degraders, with recent attention likely centered on upcoming data readouts, partnership potential, and the company's ability to validate its platform technology, as evidenced by its significant market cap of nearly $7 billion despite being pre-revenue.…
KYMR
Kymera Therapeutics, Inc. Common Stock
$99.45
Investment Opinion: Should I buy KYMR Today?
Rating: Hold. The core thesis is that Kymera represents a high-conviction, binary bet on clinical data, but its extreme valuation and proximity to 52-week highs leave minimal margin for error, making the risk/reward unfavorable for new capital at current levels.
Supporting evidence for this Hold rating includes the unanimous analyst 'Buy' consensus, but the astronomical valuation metrics (167.5x PS, 128.6x EV/Sales) provide no fundamental cushion. The stock trades at 88% of its 52-week high ($103.0), suggesting much of the near-term optimism is priced in. While the balance sheet is strong (current ratio 10.47), the negative free cash flow of -$234M TTM underscores the ongoing cash burn. The estimated revenue range for the upcoming period is wildly uncertain ($42.1M to $332.4M), reflecting the binary nature of the investment.
The two biggest risks that could invalidate a Hold thesis are 1) negative clinical data leading to a >50% de-rating, and 2) a dilutive equity offering that pressures the share price. This Hold would upgrade to a Buy only on a significant pullback (e.g., towards the $70 support level) that improves the risk/reward, or on unequivocally positive clinical data. It would downgrade to a Sell if the stock breaks above $103 on hype without corresponding fundamental news, further stretching its valuation, or if clinical setbacks emerge. Relative to its history and the biotech sector, Kymera is unequivocally overvalued on any conventional metric, but it may be fairly valued by the market for its unique platform optionality—a premium that demands perfection to maintain.
Sign up to view all
KYMR 12-Month Price Forecast
Kymera is a quintessential high-risk, high-reward biotech speculation. The neutral stance reflects the offsetting forces of compelling platform science and catastrophic valuation risk. The high analyst conviction and strong technical momentum are positive, but they are fully priced in at current levels. The investment is a binary call on clinical data, making it unsuitable for most investors. The stance would upgrade to bullish only on a meaningful pullback that improves the risk/reward profile or on the announcement of unequivocally positive clinical data. It would turn bearish if the stock breaks to new highs without fundamental justification, further stretching its valuation, or if negative clinical rumors emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kymera Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $129.28 and implied upside of +30.0% versus the current price.
Average Target
$129.28
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$80 - $129
Analyst target range
Kymera is covered by 8 analysts, and the institutional sentiment is overwhelmingly bullish, as evidenced by recent ratings actions from firms like UBS, Citigroup, and BTIG all maintaining 'Buy' or 'Overweight' stances in early 2026. The consensus recommendation is a 'Buy', though specific average target price and implied upside data are not provided in the dataset, limiting a precise calculation. The estimated revenue range for the upcoming period is wide, from a low of $42.1 million to a high of $332.4 million, with an average estimate of $211.3 million, reflecting significant uncertainty about the timing and size of potential partnership milestones. The high end of the revenue target range likely assumes successful achievement of major clinical or partnership catalysts, while the low end reflects a more conservative outlook with delays or setbacks. The wide target spread signals high uncertainty, which is standard for clinical-stage biotechs. The pattern of recent analyst actions shows stability, with no downgrades in the provided data, indicating sustained institutional confidence in the near-term story. However, the limited number of covering analysts (8) is typical for a mid-cap biotech and means price discovery can be less efficient and more volatile, especially around key data releases.
Bulls vs Bears: KYMR Investment Factors
The bull case for Kymera is powerful, driven by strong technical momentum, unanimous analyst conviction, and the transformative potential of its novel protein degradation platform. However, the bear case presents equally compelling risks centered on an extreme, unsupported valuation and the binary, high-cash-burn nature of clinical-stage biotech development. Currently, the bullish narrative has stronger evidence in the near term, as reflected in the stock's 94.7% annual gain and sustained analyst 'Buy' ratings. The single most important tension in the investment debate is the clash between the company's pioneering platform potential and its astronomical valuation (167.5x PS). The resolution of this tension depends entirely on upcoming clinical data; positive readouts could justify the premium and drive shares higher, while any setback would likely trigger a catastrophic de-rating toward more traditional biotech valuation levels.
Bullish
- Strong Clinical & Platform Validation: The company's $7 billion market cap as a pre-revenue entity demonstrates significant investor belief in its proprietary Pegasus protein degradation platform. This valuation, supported by a consensus 'Buy' rating from all 8 covering analysts, reflects confidence in the transformative potential of its lead programs (STAT6, IRAK4) for high-unmet-need diseases.
- Exceptional Momentum & Technical Strength: The stock has gained 94.72% over the past year and is trading at 88% of its 52-week high of $103.0, indicating sustained bullish momentum. Recent performance is particularly strong, with a 15.73% gain over the past month, significantly outperforming the SPY (0.74%), as shown by a 1-month relative strength of 14.99.
- Robust Balance Sheet & Low Debt: Kymera has a fortress-like balance sheet with a current ratio of 10.47 and a very low debt-to-equity ratio of 0.052. This strong financial position, with $362.8 million in cash as of Q4 2025, provides a multi-year runway to fund critical clinical trials without immediate dilution risk.
- High Analyst Conviction & Upcoming Catalysts: Analyst sentiment is unanimously bullish, with firms like UBS, Citigroup, and BTIG maintaining 'Buy' ratings. The wide estimated revenue range for the upcoming period ($42.1M low to $332.4M high, avg $211.3M) highlights the binary, high-upside nature of potential partnership or clinical milestone catalysts.
Bearish
- Extreme Valuation with No Earnings Support: The stock trades at an astronomical trailing PS ratio of 167.5x and EV/Sales of 128.6x, representing a massive premium unsupported by current financials. This valuation, near the top of its historical range, is entirely dependent on future clinical success and leaves the stock vulnerable to a severe de-rating on any setback.
- Pre-Revenue with High Cash Burn: Kymera is a clinical-stage company with minimal, lumpy revenue ($2.86M in Q4 2025, down 61.32% YoY) and deep losses (Q4 net income -$87.03M). Trailing twelve-month free cash flow is -$234.34 million, indicating a significant cash burn rate that will necessitate future dilutive financing despite the current cash balance.
- Binary Clinical Risk & High Volatility: The investment thesis hinges on binary clinical readouts for STAT6 and IRAK4 degraders. The stock's beta of 2.027 indicates it is more than twice as volatile as the market, and a recent max drawdown of -27.74% exemplifies the sharp downside risk inherent in clinical-stage biotech investing.
- Limited Financial Runway & Dilution Risk: While the balance sheet is strong now, the substantial quarterly R&D spend ($83.86M in Q4 2025) and negative FCF mean the $362.8M cash pile provides a finite runway. Equity raises are a near-certain future event, posing a persistent overhang and risk of shareholder dilution.
KYMR Technical Analysis
The stock is in a sustained, volatile uptrend, having gained 94.72% over the past year. With a current price of $90.43, it is trading at approximately 88% of its 52-week high of $103.0, indicating strong momentum but also proximity to a key resistance level that could signal overextension. This positioning near the top of its range suggests the market is pricing in significant optimism regarding clinical catalysts, but also increases the risk of a pullback if those expectations are not met. Recent momentum shows a notable acceleration, with the stock up 15.73% over the past month and 16.07% over the past three months, both figures outpacing the broader market (SPY up 0.74% and 15.14%, respectively). This strong short-term performance, coupled with a beta of 2.027, indicates the stock is more than twice as volatile as the market, characteristic of a high-beta biotech name reacting to binary clinical news. The 1-month relative strength of 14.99 confirms this recent outperformance is stock-specific, not merely a sector-wide move. Key technical levels are clearly defined by the 52-week high of $103.0 as immediate resistance and the 52-week low of $36.65 as major support. A decisive breakout above $103 would signal a new phase of the uptrend and could trigger further momentum buying. Conversely, a breakdown below the recent low near $68.14 (from January 2026) would suggest a failure of the current bullish structure. The extremely high beta of 2.027 is critical for risk management, implying amplified moves in both directions and necessitating careful position sizing for investors.
Beta
2.03
2.03x market volatility
Max Drawdown
-27.7%
Largest decline past year
52-Week Range
$37-$105
Price range past year
Annual Return
+116.8%
Cumulative gain past year
| Period | KYMR Return | S&P 500 |
|---|---|---|
| 1m | +26.1% | -0.2% |
| 3m | +33.6% | +14.0% |
| 6m | +19.6% | +7.8% |
| 1y | +116.8% | +25.3% |
| ytd | +36.7% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KYMR Fundamental Analysis
Kymera's revenue trajectory is highly volatile and not indicative of commercial operations, as it is a pre-revenue R&D company; the most recent Q4 2025 revenue was only $2.86 million, representing a year-over-year decline of 61.32%. Revenue is primarily driven by collaboration agreements and is not a reliable growth metric at this stage; the multi-quarter trend shows revenue swinging from $22.1 million in Q1 2025 to $2.86 million in Q4 2025, highlighting the lumpy, non-recurring nature of partnership payments. The fundamental investment case is entirely predicated on pipeline progression and future commercialization potential, not current sales growth. The company is deeply unprofitable, as expected for a clinical-stage biotech, with a Q4 2025 net income of -$87.03 million and a trailing net margin of -7.94%. Gross margin data is not meaningful given the minimal revenue, but operating losses are substantial, with an operating margin of -34.23% in the last quarter. The path to profitability is long-term and entirely dependent on successful clinical development, regulatory approval, and eventual product sales; the current financials reflect heavy investment in R&D, which totaled $83.86 million in Q4 2025 alone. The balance sheet is currently strong, bolstered by recent capital raises, with a robust current ratio of 10.47 and a very low debt-to-equity ratio of 0.052. However, cash burn is significant, with trailing twelve-month free cash flow deeply negative at -$234.34 million. The company ended Q4 2025 with $362.8 million in cash, which, given the burn rate, will fund operations for a limited runway, making future financing events a near-certainty and a key risk factor for equity holders.
Quarterly Revenue
$2860000.0B
2025-12
Revenue YoY Growth
-0.61%
YoY Comparison
Gross Margin
+27.63%
Latest Quarter
Free Cash Flow
$-234340000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KYMR Overvalued?
Given the company's negative net income (-$87.03M in Q4 2025) and negative EBITDA (-$85.15M), the primary valuation metric selected is the Price-to-Sales (PS) ratio, as it reflects the market's valuation of the company's platform and pipeline potential in the absence of profits. The trailing PS ratio is an astronomically high 167.5x, while the Enterprise Value-to-Sales (EV/Sales) is 128.6x, both underscoring a valuation entirely based on future expectations rather than current financials. The absence of a forward PS ratio in the data highlights the extreme uncertainty and lack of near-term revenue visibility inherent in the clinical-stage biotech model. Compared to a typical biotechnology industry average PS ratio (which often ranges in the single digits for commercial-stage firms but can be high for platform companies), Kymera's multiple represents a massive premium, justified only by the transformative potential and first-mover advantage of its protein degradation platform. This premium demands flawless execution and positive clinical data to be sustained. Historically, the stock's own PS ratio has fluctuated wildly, from a low near 31x in late 2023 to the current 167.5x. Trading near the top of its own historical valuation band suggests the market is currently pricing in a highly optimistic scenario for its lead programs. Any clinical setback could trigger a severe de-rating, as the valuation has little fundamental support from current operations and is highly sensitive to sentiment and binary clinical outcomes.
PE
-21.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -33x~-4x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and inherent to Kymera's business model. The company is pre-revenue, with Q4 2025 sales of only $2.86 million, down 61.32% year-over-year, highlighting complete dependence on non-recurring collaboration payments. Operating losses are substantial, with a Q4 operating margin of -34.23% and net income of -$87.03 million. The cash burn rate is alarming, with trailing twelve-month free cash flow at -$234.34 million. Although the current cash balance of $362.8 million and low debt-to-equity ratio of 0.052 provide a buffer, the high R&D spend ($83.86 million in Q4 alone) ensures the company will require additional capital within a few years, posing a clear dilution risk to equity holders.
Market & Competitive Risks are dominated by valuation compression. Trading at a trailing PS ratio of 167.5x and EV/Sales of 128.6x, Kymera commands a massive premium that is justified only by flawless execution. This leaves the stock exquisitely sensitive to sector-wide multiple compression, rising interest rates that discount long-dated cash flows, or any loss of its first-mover narrative advantage. The stock's beta of 2.027 confirms it is a high-volatility instrument that will amplify any negative market or sector moves. Competitive risks, while secondary to clinical risk, are real as larger pharmaceutical companies develop their own protein degradation platforms.
Worst-Case Scenario involves a clinical failure or significant safety setback for one of its lead programs (STAT6 or IRAK4). This would trigger a cascade of analyst downgrades, a loss of partnership interest, and a severe de-rating from its current premium valuation. A realistic downside target would align with the stock's 52-week low of $36.65, which represents a -59.5% decline from the current price of $90.43. Given the stock's history of a -27.74% max drawdown and high beta, a decline of 50-60% into the $36-$45 range is a plausible adverse scenario if clinical data disappoints, effectively wiping out most of the past year's gains.
FAQ
The key risks are, in order of severity: 1) Clinical Failure Risk: The entire thesis hinges on positive data for STAT6/IRAK4 degraders; failure could cause a >50% decline. 2) Valuation & Dilution Risk: The extreme PS ratio of 167.5x is unsustainable without success, and high cash burn (-$234M FCF TTM) makes future equity raises likely, diluting shareholders. 3) Financial Risk: The company is pre-revenue with deep losses (-$87M net income in Q4) and relies on a finite cash runway. 4) Market Risk: With a beta of 2.027, the stock is more than twice as volatile as the market, amplifying losses during sector downturns.
The 12-month forecast is highly bifurcated, with outcomes dependent on clinical data. The base case (50% probability) sees the stock trading between $80 and $103, as clinical progress continues without major surprises. The bull case (30% probability) targets $103 to $125 on positive data and partnership news. The bear case (20% probability) warns of a drop to $36-$60 on clinical setbacks. The most likely scenario is the base case, which assumes the company executes its trials but the extreme valuation compresses slightly over time as investors await definitive proof-of-concept.
KYMR is dramatically overvalued by any conventional financial metric. Its trailing Price-to-Sales ratio of 167.5x and Enterprise Value-to-Sales of 128.6x are astronomically high compared to the broader biotechnology sector. Historically, its own PS ratio has ranged from ~31x to current levels, indicating it is trading near the top of its valuation band. This premium implies the market is pricing in a near-perfect outcome: successful clinical validation of its platform and lucrative future partnerships. The stock is not undervalued; it is priced for perfection, leaving no room for error.
KYMR is a good buy only for speculative investors with a high risk tolerance and a long-term horizon who can withstand extreme volatility. The stock has 94.7% annual gains and unanimous analyst 'Buy' ratings, but it trades at an extreme valuation (167.5x Price/Sales) with no earnings support. The biggest downside risk is a clinical failure, which could send the stock down 50-60% toward its 52-week low of $36.65. For most investors, it is not a good buy at current levels; it would become more attractive only after a significant pullback or upon confirmation of positive clinical data.
KYMR is unsuitable for short-term trading due to its high volatility (beta 2.027) and sensitivity to binary clinical news, which can cause sudden, unpredictable swings. It is only suitable for long-term investors (minimum 3-5 year horizon) who can weather this volatility and are betting on the long-term validation of the protein degradation platform. The company pays no dividend and has no earnings visibility, eliminating it as an income or value play. Given the long clinical and regulatory pathway ahead, investors must be prepared to hold through multiple data readouts and potential capital raises.